Rheumatoid Arthritis

Major adverse cardiovascular event rates for baricitinib stabilize over time.

Methotrexate discontinuation was not observed to impact rheumatoid arthritis treatment with tocilizumab, according to an abstract presented at the 2017 American College of Rheumatology Annual Meeting.

Some patients with rheumatoid arthritis require a refined treat-to-target plan.

Low incidence of 14-3-3η in patients with long-term RA, chronic HCV with arthralgias.

Flares and immune-related adverse events are common among patients with rheumatologic diseases but can often be successfully managed.

Biomarker identification may improve abatacept (Orencia) treatment for rheumatoid arthritis.

Patients with rheumatoid arthritis who switched to biologics or triple therapy had a longer time to treatment failure versus augmented oral methotrexate.

The emergence of biosimilars will reduce spending on biologics by 3% through 2027.

Two supplemental biologics license applications granted to golimumab to treat adults with psoriatic arthritis and adults with active ankylosing spondylitis.

Top news of the week from Specialty Pharmacy Times.

Many patients with rheumatoid arthritis feel their employers do not understand their condition.

Spending for adalimumab has tripled from 2012 from $4.5 billion.

Sirukumab is an anti-interleukin-6 monoclonal antibody designed to block the IL-6 pathway in a different way than currently approved IL-6 inhibitors.

Results of the case could alter the future of the biosimilar marketplace.

Medication compliance is associated with lower overall and disease-related healthcare costs in patients with moderate to severe rheumatoid arthritis receiving biologic therapies.

Ibuprofen use may result in hypertension for patients with arthritis and cardiovascular risks.

Top news of the week from Specialty Pharmacy Times.

Switching from etanercept to biosimilar was not associated with treatment-emergent adverse events in rheumatoid arthritis.

Patients who received the shingles vaccine before treatment for arthritis with tofacitinib showed robust immune responses.

Live varicella-zoster vaccine is adequately immunogenic in patients with rheumatoid arthritis starting treatment with tofacitinib.

Use of oral contraceptives for 7 or more consecutive years associated with lower risk of rheumatoid arthritis.

Top news of the week from Specialty Pharmacy Times.

Hibernating innate lymphoid cells allows inflammation to persist in rheumatoid arthritis.

Work-related factors, such as noxious airborne agents, may elevate the risk of rheumatoid arthritis.

Novel treatment effective against rheumatoid arthritis also produced a marked improvement in skin lesions caused by atopic dermatitis.

Anti-rheumatic drug suppresses activation of a molecular pathway responsible for the disease.

If approved, Xeljanz will be the first Janus kinase inhibitor for psoriatic arthritis.

Sirukumab is designed to treat adults with moderately-to-severely active rheumatoid arthritis.

New treatment strategies for rheumatoid arthritis led to a reduction in congestive heart failure and cardiovascular mortality after the year 2000.

Study will compare the pharmacokinetics and clinical outcomes between Humira biosimilar and its reference product in the treatment of moderate-to-severe chronic plaque psoriasis.